Zacks Investment Research upgraded shares of Ohr Pharmaceuticals, Inc. (NASDAQ:OHRP) from a hold rating to a buy rating in a research report sent to investors on Wednesday morning. The brokerage currently has $0.75 price target on the biotechnology company’s stock.

According to Zacks, “Ohr Pharmaceutical, Inc. is a pharmaceutical company. It is focused on the development of novel therapeutics for the treatment of cancer cachexia, wet form of age-related macular degeneration and ophthalmic neovascularization disorders. Ohr Pharmaceutical, Inc. is headquartered in New York. “

Separately, HC Wainwright set a $10.00 price target on shares of Ohr Pharmaceuticals and gave the stock a buy rating in a research note on Wednesday, August 16th.

Ohr Pharmaceuticals (NASDAQ OHRP) traded up 0.6046% during trading on Wednesday, hitting $0.6489. The stock had a trading volume of 192,438 shares. The company’s market cap is $36.48 million. Ohr Pharmaceuticals has a 52 week low of $0.56 and a 52 week high of $3.20. The stock has a 50-day moving average price of $0.70 and a 200-day moving average price of $0.67.

Ohr Pharmaceuticals (NASDAQ:OHRP) last announced its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.18. Equities analysts predict that Ohr Pharmaceuticals will post ($0.95) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Ohr Pharmaceuticals, Inc. (OHRP) Lifted to “Buy” at Zacks Investment Research” was reported by Daily Political and is the property of of Daily Political. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at

A number of institutional investors and hedge funds have recently made changes to their positions in OHRP. Renaissance Technologies LLC lifted its stake in Ohr Pharmaceuticals by 242.3% during the first quarter. Renaissance Technologies LLC now owns 229,709 shares of the biotechnology company’s stock worth $191,000 after purchasing an additional 162,600 shares during the period. Cannell Peter B & Co. Inc. bought a new position in Ohr Pharmaceuticals during the second quarter worth about $187,000. Finally, Vanguard Group Inc. lifted its stake in Ohr Pharmaceuticals by 0.7% during the second quarter. Vanguard Group Inc. now owns 812,418 shares of the biotechnology company’s stock worth $520,000 after purchasing an additional 5,481 shares during the period. Hedge funds and other institutional investors own 7.03% of the company’s stock.

About Ohr Pharmaceuticals

OHR Pharmaceutical, Inc, a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes.

Get a free copy of the Zacks research report on Ohr Pharmaceuticals (OHRP)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Ohr Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ohr Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.